Clinical trials: CTLA-4

Psoriasis

Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris

• Completed
• Age: 18 to 65 years
• Phase 2
• Results posted

The purpose of this study is to determine if the use of ustekinumab, followed by abatacept, will prevent relapse in people with moderate to severe plaque psoriasis.

Trial name

PAUSE (NCT01999868)

Testing

Ustekinumab, Abatacept

Where

10 sites in United States, Canada

Volunteers

108 people

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)